Agreement - March 2, 2021
Beactica enters license and collaboration agreement
Beactica Therapeutics and Oscotec, a Korean drug development company, have announced a new research development and licensing agreement. The two companies will initially jointly collaborate concerning research and early preclinical development of novel anticancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization, […]
Drug Development Pharma - November 23, 2017
Beactica awarded 2 MSEK funding
Beactica has been awarded 2 MSEK by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its LSD1 programme. The LSD1 programme aims to develop a novel class of compounds with the potential to radically improve the current treatment of glioblastoma, an aggressive brain tumour with 40 000 annual cases in the EU and the […]
Funding - November 25, 2014
Beactica Receives Grant
Beactica, the Swedish fragment-based drug discovery company, announced that it has been awarded a SEK 3.0 million grant from the Swedish Governmental Agency for Innovation Systems (VINNOVA). The grant will be used to support the development of a new epigenetic drug for treatment of cancer. The goal of Beactica’s project is to develop novel compounds for […]
Collaboration - June 10, 2014
Beactica and Medivir in drug discovery collaboration
The Swedish fragment-based drug discovery company has entered into an agreement with Medivir. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement have not been disclosed. “We are pleased that Medivir has selected Beactica to advance one […]
